摘要
目的 :研究卵巢癌拓扑异构酶Ⅱα表达与化疗敏感性的关系。方法 :采用免疫组化Envision法检测 81例上皮性卵巢癌TopoⅡα的表达 ,并予以 3～ 8个疗程以铂类为主的联合化疗。结果 :低分化卵巢癌TopoⅡα的表达明显高于中、高分化者 (P =0 .0 4 7) ,术前行化疗的卵巢癌TopoⅡα表达明显低于术前未化疗者 (P =0 .0 0 2 ) ,而复发性卵巢癌TopoⅡα表达再次升高 ;不考虑MDR1因素时 ,TopoⅡα与化疗敏感性间未见明显的相关性 (P =0 .0 73) ,而在排除MDR1影响后 ,TopoⅡα表达与化疗疗效间具有明显相关性 (P=0 .0 2 6 ) ,阳性表达时化疗效果好 ,未发现TopoⅡα的表达强度与化疗疗效间有相关性(P =0 .98)。结论 :TopoⅡα表达与卵巢癌分化程度有关 ,化疗影响TopoⅡα的表达 ,复发病例TopoⅡα表达重新增强 ,MDR1阴性时 ,TopoⅡα表达与化疗敏感性间具有明显相关性。因此 ,可以根据卵巢癌TopoⅡα表达情况 。
Objective:To investigate the correlation between Topo Ⅱα expression and chemosensitivity in epithelial ovarian carcinoma (EOC).Methods:The expression of Topo Ⅱα was determined by immunohistochemistry in 81 resected specimens of EOC.All the patients received 3～8 courses of platinum based chemotherapy.Results: The positive rate of Topo Ⅱα in poorly differentiated cancer was higher than that in well differentiated ones(P=0.047).The positive expression in the primary EOC without any chemotherapy before operation was higher thanthat in the EOC with chemotherapy and the expression of Topo Ⅱα was reintensified in recurrent EOC.The response rate to the platinum based chemotherapy wasnot significantly associated with Topo Ⅱα expression,while excluding the influence of MDR1 ,the chemosensitivity in the Topo Ⅱα positive group was higher than that in the negative group(P=0.026). Conclusions:The expression of Topo Ⅱα in EOC is associated with the differentiation of the tumor and influenced by chemotherapy.There is correlation between the positive expression of Topo Ⅱα and chemosensitivity in theEOC.The expression of Topo Ⅱα may be useful for prediction of a clinical response to the platinum based chemotherapy.
出处
《现代妇产科进展》
CSCD
2002年第4期245-247,共3页
Progress in Obstetrics and Gynecology
